Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib
CONCLUSIONS: Tirabrutinib generally maintains KPS and QoL scores with some improvements in specific QoL items in patients with r/r PCNSL.PMID:37744697 | PMC:PMC10517093 | DOI:10.1093/noajnl/vdad109 (Source: Adv Data)
Source: Adv Data - September 25, 2023 Category: Epidemiology Authors: Yoshiki Arakawa Yoshitaka Narita Motoo Nagane Kazuhiko Mishima Yasuhito Terui Hajime Yonezawa Katsunori Asai Noriko Fukuhara Kazuhiko Sugiyama Naoki Shinojima Arata Aoi Ryo Nishikawa Source Type: research
Cancers, Vol. 15, Pages 4584: Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study
In conclusion, the pretreatment STB could be considered a novel biomarker to predict the clinical outcomes in patients with PCNSL receiving high-dose methotrexate-based combination immunochemotherapy. (Source: Cancers)
Source: Cancers - September 15, 2023 Category: Cancer & Oncology Authors: Jiazhen Cao Shengjie Li Danhui Li Wei Hua Lin Guo Zuguang Xia Tags: Article Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
